Last updated on April 2019

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

Brief description of study

This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks and duration of administration for 1 year in patients with high-risk essential thrombocythemia.

Clinical Study Identifier: NCT03232177

Find a site near you

Start Over

Hallym UNIV. Medical Center

Anyang, Korea, Republic of
  Connect »

Inha University Hospital

Incheon, Korea, Republic of
  Connect »

Jeju National University Hospital

Jeju City, Korea, Republic of
  Connect »

Hallym UNIV. Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.